PFN2 (profilin 2) is an actin-binding protein that plays diverse roles in cytoskeletal regulation, disease pathogenesis, and cellular signaling. The protein functions as a regulator of actin dynamics and exhibits a unique functional relationship with the actin N-terminal acetyltransferase NAA80, where PFN2 binding specifically increases NAA80's catalytic activity and promotes actin N-terminal acetylation 1. PFN2 also regulates endocytosis and ERK signaling pathways, with its expression controlled by miR-290 family microRNAs in embryonic stem cells, affecting cell cycle progression and differentiation 2. In disease contexts, PFN2 dysregulation contributes to multiple pathological conditions. Reduced PFN2 expression serves as a common molecular determinant in Charcot-Marie-Tooth type 2 neuropathy across different genetic subtypes, with progressive age-related decline in patients compared to healthy controls 3. Conversely, elevated PFN2 expression correlates with poor prognosis in head and neck squamous cell carcinoma and promotes cardiac ferroptosis during myocardial ischemia-reperfusion injury through m6A-dependent mRNA stabilization 4 5. PFN2 also facilitates epithelial-mesenchymal transition via the SMAD/TGF-β1 pathway and can be delivered through urinary extracellular vesicles 6. These findings establish PFN2 as a multifunctional cytoskeletal protein with significant therapeutic potential across diverse disease states.